MIM
BCAX

MetLife Investment Management’s Bicara Therapeutics BCAX Stock Holding History

MetLife Investment Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$775K Buy
26,088
+7,728
+42% +$172K ﹤0.01% 1657
2026
Q1 		$365K Sell
18,360
-3,159
-15% -$54.4K ﹤0.01% 1906
2025
Q4 		$362K Hold
21,519
– – ﹤0.01% 1947
2025
Q3 		$340K Buy
+21,519
New +$241K ﹤0.01% 2013
2025
Q2 		– Sell
-12,163
Closed -$158K – 2938
2025
Q1 		$158K Hold
12,163
– – ﹤0.01% 2314
2024
Q4 		$212K Buy
+12,163
New +$253K ﹤0.01% 2277

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MetLife Investment Management's BCAX Position: Q2 2026 in Review

MetLife Investment Management increased its Bicara Therapeutics (BCAX) stake by 42% in Q2 2026, buying an estimated $172K and bringing the position to 26,088 shares worth $775K. The position accounts for ﹤0.01% of the portfolio, ranked #1657.

MetLife Investment Management first reported a position in BCAX in Q4 2024 and has held it in 6 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • MetLife Investment Management held 26,088 shares of Bicara Therapeutics worth $775K as of Q2 2026.
  • MetLife Investment Management bought 7,728 Bicara Therapeutics shares in Q2 2026, an estimated $172K.
  • Bicara Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1657 holding.
  • MetLife Investment Management first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.